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The NF-AT transcription factors regulated by the phosphatase calcineurin play a role in breast cancer metas-
tasis-promoting tumor cell invasion. Metastasis is a multistep process requiring angiogenesis and endothe-
lial activation. NF-AT is also expressed in endothelial cells, and calcineurin-NF-AT signaling is an important
downstream effector of the proangiogenic cytokine VEGF. One isoform of the endogenous calcineurin
regulator, Down syndrome candidate region-1 (DSCR1.Ex4), suppresses calcineurin-NFAT signaling block-
ing endothelial proliferation. However, overexpression of the other DSCR1 isoform (DSCR1.Ex1) may
promote angiogenesis. We report that targeted deletion of both isoforms leads to hyperactivated calcineurin
and precocious endothelial apoptosis, inhibiting formation of an effective tumor vasculature and suppressing
tumorigenesis. Treatment with the specific pharmacological calcineurin inhibitor cyclosporin A rescues this
endothelial defect in DSCR1/ mice, restoring tumor growth.INTRODUCTION
Oncogenic mutations are thought to be causally involved in the
genesis, progression and maintenance of human cancers (Folk-
man and Ryeom, 2005). Nonetheless, it is also well accepted that
tumor evolution, invasion, and metastasis involve obligate and
complex interactions between cancer cells and their surrounding
host microenvironment (Folkman and Ryeom, 2005). In particu-
lar, macroscopic growth of tumor masses requires not only
tumor cell proliferation but also concomitant angiogenesis, for
which endothelial cell activation is a prerequisite (Folkman and
Ryeom, 2005). Endothelial cell activation and proliferation is reg-
ulated by multiple proangiogenic factors, of which the most
widely studied is vascular endothelial growth factor (VEGF).
VEGF is a potent endothelial cell mitogen in vivo (Ferrara,
2004) whose function is critical for angiogenesis in both normal
development and adult remodeling tissues as well as in tumor
cell expansion and invasion (Ferrara, 2004).420 Cancer Cell 13, 420–431, May 2008 ª2008 Elsevier Inc.Of the many downstream effectors of VEGF function in endo-
thelial cells, one is the calcineurin-NFAT signaling pathway. Fol-
lowing VEGF ligation of its receptors VEGFR1 and VEGFR2,
PLCg is activated with subsequent increases in intracellular
calcium levels (Ferrara et al., 2003). Increased calcium activates
the serine/threonine phosphatase calcineurin, which, in turn, de-
phosphorylates the NF-AT family of transcription factors and
triggers their nuclear accumulation (Crabtree and Olson, 2002).
NF-AT transactivates multiple proangiogenic genes, such as
those encoding cyclooxygenase 2, E-selectin, and tissue factor
(Hernandez et al., 2001; Johnson et al., 2003).
The endogenous calcineurin inhibitor Down syndrome
candidate region-1 (DSCR1), also known as RCAN1, has two
differentially regulated isoforms (Rothermel et al., 2003).
Overexpression of the inducible isoform, DSCR1.Ex4, blocks
VEGF-calcineurin-NF-AT-mediated activation of endothelial
cells in vitro (Hesser et al., 2004; Iizuka et al., 2004; Minami
et al., 2004; Yao and Duh, 2004). In contrast, overexpression ofSIGNIFICANCE
Recent anticancer therapies target endothelial cells to block tumor vascularization. Endothelial proliferation is mediated by
cytokines like VEGF that activate the endothelium via their cell surface receptors. Antiangiogenic therapy has focused on
preventing endothelial activation by sequestering angiogenic factors or targeting their receptors. Here we show that angio-
genesismay be regulated in an endothelial cell-autonomousmanner downstream of VEGF viamodulation of calcineurin sig-
naling. The calcineurin inhibitor DSCR1 attenuates VEGF-calcineurin-NF-AT signaling in endothelial cells. Upon loss of
DSCR1, VEGF-calcineurin signaling is hyperactivated, leading to premature endothelial apoptosis and, ultimately, suppres-
sion of tumor angiogenesis. Our data illustrate that strict regulation of calcineurin activity in endothelial cells is required for
tumor angiogenesis. Thus, the calcineurin pathway represents a tractable target for suppressing tumor growth.
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Loss of DSCR1 Suppresses Tumor Angiogenesisthe constitutive isoform DSCR1.Ex1 promotes angiogenesis in
vitro (Qin et al., 2006). Hence, the overall influence of the
DSCR1 gene on VEGF-calcineurin-NF-AT-mediated activation
of endothelial cells in particular, and on normal and tumor vascu-
lar endothelium in general, remains unclear. However, a microar-
ray study looking at gene transcription following VEGF treatment
of endothelial cells found DSCR1.Ex4 to be the most highly
upregulated transcript, consistent with an important role for
DSCR1 in VEGF-mediated angiogenesis (Abe and Sato, 2001).
Recently, a role for the calcineurin substrate NF-AT in cancer
progression has been identified. Most notably, NF-AT is ex-
pressed in breast cancer cells, where it mediates cancer cell
invasion and metastasis as a consequence of downregulation
of AKT (Jauliac et al., 2002). Such observations suggest that
the calcineurin-NFAT pathway plays a significant role in tumor
growth through its actions in cancer cells. However, the extent
to which DSCR1 regulates NF-AT activity in cancer cells, either
independently or together with AKT, is unknown.
To examine specifically the contributions of DSCR1 and the
putative calcineurin-NF-AT-DSCR1 pathway to tumor progres-
sion and angiogenesis, we made use of mice with a targeted
deletion of both DSCR1 isoforms (Ryeom et al., 2003). Inactiva-
tion of DSCR1, encoding both DSCR1.Ex1 and DSCR1.Ex4
isoforms, elicits a low-penetrance developmental defect associ-
ated with cerebral vascular degeneration. Importantly, however,
the great majority of mice survive into adulthood but exhibit ele-
vated and persistent activation of calcineurin. Such calcineurin
hyperactivity triggers apoptosis of activated endothelial cells,
with the effect of significantly suppressing subcutaneous and
metastatic tumor growth by preventing the elaboration of stable
tumor vasculature. Modest pharmacological suppression of
calcineurin activity restores tumor growth in DSCR1/ mice,
confirming the idea that dysregulated calcineurin signaling in
the vascular endothelium is directly responsible for suppressing
tumor growth. Hence, the calcineurin-NF-AT-DSCR1 pathway
constitutes a target for anticancer therapy.
RESULTS
Inactivation of DSCR1 Suppresses Tumor Growth
Since angiogenesis is necessary for macroscopic tumor expan-
sion, we examined the impact of DSCR1 status on tumor growth
in vivo. Murine renal carcinoma (RENCA) and colon carcinoma
(MC26) tumor cells were inoculated into syngeneic DSCR1
wild-type (WT) and DSCR1/ mice and rates of growth mea-
sured over time. Growth of both RENCA and MC26 tumors
was significantly retarded in DSCR1/ mice relative to
DSCR1 WT controls (Figure 1A), with RENCA tumor growth
more affected than that of MC26. One difference between these
two tumor cell lines was that VEGF secretion was some 7-fold
greater in RENCA versus MC26 tumors, as measured by ELISA
(Figure 1B).
To establish whether differences in tumor growth were due to
modulation of VEGF production by tumor cells in DSCR1/
mice, we immunostained RENCA tumors from DSCR1 WT and
DSCR1/ mice for VEGF but found no significant differences in
similar sized tumors (Figure S1A available online). DSCR1 status
in tumor vessels from DSCR1 WT and DSCR1/ mice was con-
firmed by costaining tumor tissue sections with anti-CD31 andanti-DSCR1 antibodies. DSCR1 colocalized with CD31 in tumors
harvested from wild-type mice but wasabsent fromtumorsderived
from DSCR1/ animals (Figure 1C). Microvessel density was
considerably increased in both RENCA and MC26 tumors iso-
lated from wild-type mice versus tumors harvested from
DSCR1/ animals at the same time after tumor cell inoculation
(Figure 1D; Figure S1C). Finally, to ensure that tumor growth
was suppressed and not merely delayed in DSCR1/ mice, we
allowed MC26 colon carcinoma tumors in the DSCR1/ mice
to continue to grow for 2 weeks after theirDSCR1WT equivalents
had been euthanized because of large tumor burden (Figures S1B
and S1C). At this time (day 31 after tumor cell inoculation) all
tumors in DSCR1/ mice appeared necrotic (Figure S1C) and
exhibited similar tumor volumes as on day 15 (Figure S1B),
consistent with suppression of tumor growth due to the inability
to form and maintain a stable tumor vasculature. To confirm this,
RENCA and MC26 tumors were harvested from WT and
DSCR1/ mice and coimmunostained with the endothelial-spe-
cificmarker CD31and forTUNELreactivity to identifyapoptotic en-
dothelial cells. Tumors fromDSCR1/mice generally had shorter,
stunted vessels with most of the endothelial cells in longer vessels
colocalizing with TUNEL-positive staining (Figure 1E; Figure S1D).
Blood vessel maturation is characterized by endothelial cells
surrounded by smooth muscle cells and pericytes as indicated
by alpha smooth muscle actin (aSMA) immunostaining (Ozawa
et al., 2005). Tumors fromDSCR1/ mice demonstrated a signif-
icant reduction in SMA-positive and CD31-double-positive blood
vessels (Figure 1F) ascompared to tumors from wild-type mice. To
characterize further the extent of tumor neovascularization in
DSCR1 WT versus DSCR1/ mice, we used an in vivo tumor
Miles permeability assay. Tumor-bearing mice were injected intra-
venously with Evans blue dye and, 30 min later, perfused with
saline to remove dye from the vascular lumen. Tumors were then
harvested and dye extracted and quantified spectrophotometri-
cally.After normalization to tumor size and weight, we found signif-
icantly more dye present in tumors from DSCR1 WT mice relative
to their DSCR1/ counterparts (Figure 1G), implicating the pres-
ence of a more extensive vascular network in tumors harvested
from wild-type mice allowing the accumulation of more dye.
Calcineurin Signaling in Endothelial Cells Is Hyperactive
in the Absence of DSCR1
To explore directly the role of DSCR1 in attenuating VEGF signal-
ing, we isolated primary microvascular endothelial cells from
bothDSCR1WT andDSCR1/mice and compared the dynam-
ics of VEGF-calcineurin signaling in vitro. Endothelial cell identity
was confirmed by both morphology and immunofluorescence
analysis using an anti-VEGFR2 antibody (Figures S2A and
S2B). The absence of DSCR1 expression in DSCR1/ endothe-
lial cells was confirmed by immunofluorescence (Figure S2C)
and western blotting using a DSCR1-specific monoclonal anti-
body (Ryeom et al., 2003). DSCR1 WT endothelial cells treated
with 10 ng/ml VEGF for 1 hr demonstrated expression of the
inducible, 25 kDa DSCR1 isoform (DSCR1.Ex4), while similarly
treated DSCR1/ endothelial cells expressed neither constitu-
tive (38 kDa; DSCR1.Ex1) nor inducible DSCR1 isoforms
(Figure 2A).
Since calcineurin signaling is mediated via nuclear import of the
NF-AT transcription factor family, we next examined the kineticsCancer Cell 13, 420–431, May 2008 ª2008 Elsevier Inc. 421
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Loss of DSCR1 Suppresses Tumor Angiogenesisof endogenous NF-AT translocation inDSCR1WT andDSCR1/
endothelial cells. NF-AT nuclear import has been reported after
VEGF treatment of endothelial cells for 30 min in a calcineurin-de-
pendent manner (Hernandez et al., 2001; Johnson et al., 2003).
Within 5 min of VEGF exposure, 39.2% (±1.4) ofDSCR1/ endo-
thelial cells exhibited NF-ATc1 nuclear localization as compared
to only 7.9% (±4.0) of wild-type endothelial cells (Figure 2B). In-
deed, even untreated DSCR1/ endothelial cells showed some
NF-ATc1 nuclear localization (Figure 2C), consistent with the no-
tion that calcineurin is hyperactivated in DSCR1/ cells even in
the absence of a calcium agonist. Therefore, to ascertain that
the precocious NF-ATc1 nuclear localization that we observed
in DSCR1/ endothelial cells was indeed dependent on calci-
neurin, we treated DSCR1/ cells with the pharmacological cal-
cineurin inhibitor cyclosporin A (CsA) (Liu et al., 1999). This dra-
matically reduced the proportion of DSCR1/ cells exhibiting
nuclear NF-ATc1 5 min after VEGF exposure to only 3.3% (±0.5)
(Figures 2B and 2C).
Figure 1. Tumor Angiogenesis Is Sup-
pressed in DSCR1/ Mice
(A) Subcutaneous tumor growth of two different
syngeneic mouse tumor cells, renal cell carcinoma
(RENCA) and colon carcinoma (MC26), was
impaired in DSCR1/ mice.
(B) VEGF production by RENCA and MC26 tumor
cells as measured by ELISA.
(C) RENCA tumors harvested from WT and
DSCR1/ mice are coimmunostained with anti-
CD31 and anti-DSCR1. Scale bar, 50 mM.
(D) Microvessel density (MVD) per high-powered
field (hpf) of MC26 tumors harvested from
DSCR1/ animals was significantly reduced as
compared to tumors from WT mice.
(E) RENCA tumors from DSCR1 WT mice showed
almost no TUNEL-positive cells, while RENCA
tumors from DSCR1/ mice show colocalization
of the endothelial-specific marker CD31 and
TUNEL reactivity (arrows) indicating apoptotic
cells. Scale bar, 50 mM.
(F) Microvessel integrity was impaired in tumors
harvested from DSCR1/ animals as demon-
strated by decreased colocalization of CD31 and
alpha smooth muscle actin (aSMA) immunofluo-
rescence. Scale bar, 50 mM.
(G) Tumors from DSCR1 WT mice with more
extensive vasculature have significantly higher
levels of Evans blue dye compared to tumors
from DSCR1/ mice. All data are represented
as mean ± SEM.
To confirm the biological significance
of the premature nuclear import of NF-
ATc1 in DSCR1/ endothelial cells, we
examined expression of the proangio-
genic NF-AT target gene cyclooxyge-
nase-2 (Cox-2) (Hernandez et al., 2001).
Compared with DSCR1 WT endothelial
cells, Cox-2 expression was significantly
upregulated in DSCR1/ endothelial
cells within only 15 min of VEGF exposure
(Figure 2D). Thus, DSCR1 modulates ex-
pression of proangiogenic genes regulated by the VEGF-calci-
neurin-NF-AT pathway.
Finally, we assessed whether the absence of DSCR1 in-
creased the sensitivity of endothelial cells to VEGF signaling.
Indeed, exposure of DSCR1 WT cells to low-dose VEGF (1–2.5
ng/ml) had negligible impact on 3H-thymidine incorporation but
potently promoted proliferation of their DSCR1/ counterparts
(Figure 2E). Thus, the absence of DSCR1 significantly sensitizes
cells to VEGF-induced signaling, most likely due to an inability to
attenuate VEGF-calcineurin signaling.
Hyperactivation of the VEGF-Calcineurin-NF-AT
Pathway in DSCR1-Deficient Endothelial Cells
Suppresses Proliferation
While a simple model might suggest that hypersensitivity to VEGF
might promote VEGF-induced endothelial cell proliferation, evi-
dence suggests that the opposite may be true, in the main be-
cause constitutive activation of calcineurin is a potent inducer422 Cancer Cell 13, 420–431, May 2008 ª2008 Elsevier Inc.
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Loss of DSCR1 Suppresses Tumor Angiogenesisof apoptosis (Wang et al., 1999). Consistent with this, exposure
to mitogenic levels of VEGF (50–500 ng/ml) induced consider-
ably greater expansion in numbers of DSCR1 WT versus
DSCR1/ primary endothelial cells after 3 days (Figure 3A),
Figure 2. Hyperactivated Calcineurin Sig-
naling in DSCR1/ Endothelial Cells
(A) Western blot analysis of DSCR1 WT and
DSCR1/ endothelial cell lysates probed with
anti-DSCR1 monoclonal antibody, with or without
VEGF (10 ng/ml) treatment for 1 hr. Blots were
reprobed with b-actin as a loading control.
(B) Quantification of NF-ATc1 nuclear localization
in DSCR1 WT and DSCR1/ endothelial cells
after treatment with VEGF (10 ng/ml) with or with-
out 0.5 mM cyclosporin A (CsA) for 5 min. Percent
of cells with nuclear NF-ATc1 expression indi-
cated as mean ± SEM.
(C) Subcellular localization of NF-ATc1 following
VEGF treatment (10 ng/ml) of endothelial cells af-
ter 5 min with and without 0.5 mM CsA. Hoechst
staining reveals nuclei. Scale bar, 20 mM.
(D) Representative western blot of Cox-2 expres-
sion inDSCR1WT andDSCR1/ endothelial cells
after VEGF treatment for 15 min. Blots were
reprobed with b-actin as a loading control. Densi-
tometric ratio of Cox2/b-actin signal in DSCR1 WT
and DSCR1/ endothelial cell lysates (right).
(E) 3H-thymidine uptake by DSCR1 WT and
DSCR1/ endothelial cells after 3 days with basal
media supplemented with low concentrations of
VEGF. Data are represented as mean ± SEM.
indicating a deficit in VEGF-induced ex-
pansion of DSCR1/ endothelial cells.
To ascertain whether this deficit in
DSCR1/ cell proliferation was depen-
dent on calcineurin, we asked whether it
could be reversed with the calcineurin
inhibitor CsA. However, since normal
calcineurin function is required for
VEGF-induced endothelial cell prolifera-
tion, we first had to identify a concentra-
tion of CsA that dampens but did not
completely eliminate calcineurin activity.
Proliferation of wild-type endothelial cells
was examined after 3 days exposure to
100 ng/ml VEGF treatment in the pres-
ence of CsA concentrations ranging
Figure 3. DSCR1/ Endothelial Cells Dem-
onstrate a Defect in VEGF-Mediated Prolif-
eration that Is Rescued by Cyclosporin A
Treatment
(A) Growth of DSCR1 WT and DSCR1/ endothe-
lial cells after 3 days in vitro in basal media supple-
mented with the indicated concentrations of
VEGF.
(B) Low-dose cyclosporin A (CsA) (10 nM) treat-
ment rescued the proliferation defect seen in
DSCR1/ endothelial cells. All data are repre-
sented as mean ± SEM.
from 25 nM to 500 nM (Figure S3). This indicated that CsA doses
as low as 25 nM suppressed VEGF-induced cell proliferation.
However, 10 nM CsA treatment effectively rescued the deficient
VEGF-mediated growth of DSCR1/ endothelial cells withoutCancer Cell 13, 420–431, May 2008 ª2008 Elsevier Inc. 423
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(Figure 3B). Taken together, these data confirm that the prolifer-
ation defect observed in DSCR1/ endothelial cells is indeed
calcineurin dependent.
Hyperactivation of the VEGF-Calcineurin-NF-AT
Pathway Triggers Apoptosis in DSCR1-Deficient
Endothelial Cells
The failure of DSCR1/ endothelial cell cultures to expand un-
der the influence of VEGF could be due to decreased prolifer-
ation and/or increased apoptosis. To examine these possibili-
ties, we initially measured cell viability by determining ATP
content of DSCR1/ cultures after 3 days exposure to
VEGF. In the presence of increasing concentrations of VEGF,
DSCR1/ endothelial cells demonstrated decreased levels of
ATP, further confirming a lack of endothelial cell expansion
(Figure S4A).
Interestingly, the effects of DSCR1 inactivation could be reca-
pitulated by exposing wild-type endothelial cells to extremely
high levels of VEGF, which presumably overrides the DSCR1
feedback attenuation. At VEGF levels of 100 ng/ml VEGF and
Figure 4. VEGF Induction of Apoptosis in
Endothelial Cells
(A) Proliferation of endothelial cells (HMVEC) after
3 days in vitro in basal media supplemented with
the indicated concentrations of VEGF. Data are
represented as mean ± SEM.
(B) Annexin V and Hoechst immunofluorescence of
HMVEC after treatment with the indicated concen-
trations of VEGF for 48–72 hr. Scale bar, 25 mM.
(C)Phospho-BAD levelsare decreased inDSCR1/
endothelial cells as compared to DSCR1 WT endo-
thelial cells after VEGF treatment for 48–72 hr.
(D) DSCR1/ endothelial cells (bottom row) dem-
onstrate upregulated inducible nitric oxide syn-
thase (eNOS) expression in response to 100 ng/ml
VEGF as compared to DSCR1 WT endothelial
cells (top row). DSCR1 WT endothelial cells only
express eNOS after treatment with 1000 ng/ml
VEGF. Scale bar, 25 mM.
(E) Caspase-3 activity is significantly upregulated
in DSCR1/ endothelial cells after VEGF treat-
ment and blocked by a caspase-3 inhibitor. Data
are represented as mean ± SEM.
(F) VEGF-induced proliferation defect ofDSCR1/
endothelial cells is reversed by treatment with the
caspase inhibitor, zVAD-fmk. Data are represented
as mean ± SEM.
higher, we observed significant suppres-
sion of growth in WT endothelial cell cul-
tures, similar to that observed in
DSCR1/ cells, albeit at 10-fold lower
VEGF concentrations (Figure 4A). Annexin
V immunostaining confirmed that this was
due to apoptosis (Figure 4B). Thus, we
postulated that non-physiologically high
levels of VEGF phenocopy the effect of
DSCR1 inactivation in DSCR1 WT endo-
thelial cells, so we next examined DSCR1/ endothelial cell
apoptosis after VEGF treatment.
In addition to its actions on NF-AT, calcineurin directly de-
phosphorylates the proapoptotic protein BAD, thus promoting
its proapoptotic activity through neutralization of Bcl-xL and, ul-
timately, caspase-3 activation and apoptosis (Wang et al., 1999)
(Figure S4B). To determine whether BAD dephosphorylation
could play a role in apoptosis of VEGF-treated DSCR1/ cells,
we directly examined phospho-BAD levels in WT and DSCR1/
endothelial cells with and without VEGF exposure (100 ng/ml).
Total cytoplasmic BAD was immunoprecipitated followed by
western blot analysis with a phospho-BAD-specific antibody
(Figure 4C). While there was no significant difference in phos-
pho-BAD levels between untreated WT or DSCR1/ endothelial
cells, the proportion of total Bad phosphorylated was sharply
decreased in DSCR1/ (but not DSCR1 WT) endothelial cells
after VEGF treatment (Figure 4C; Figure S4C). These data are
consistent with a direct role for hyperactive calcineurin signaling
in promoting apoptosis through BAD activation.
Calcineurin is also known to regulate apoptosis in endothelial
cells via the nitric oxide pathway. Calcineurin-mediated NF-AT
dephosphorylation allows NF-AT to transactivate endothelial424 Cancer Cell 13, 420–431, May 2008 ª2008 Elsevier Inc.
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Under physiological conditions, eNOS and nitric oxide (NO)
can stimulate endothelial proliferation and migration. However,
at high concentrations, NO is proapoptotic in several tissue
types, including endothelium (Dimmeler and Zeiher, 1999). To
determine whether eNOS and NO production are upregulated
in DSCR1/ endothelial cells, we utilized the small molecule
dye 4,5-diaminofluorescein diacetate (DAF-2DA), which is
cleaved by eNOS emitting a fluorescence signal that is quantita-
tively dependent upon NO production in the cell (Rossig et al.,
2002). After 100 ng/ml VEGF treatment for 24–36 hr, DAF-2DA
fluorescence was significantly greater in DSCR1/ versus
DSCR1 WT endothelial cells (Figure 4D). However, upregulation
of DAF-2DA fluorescence was observed in DSCR1 WT endothe-
lial cells by exposing DSCR1 WT endothelial cells to 10-fold
higher levels of VEGF (1000 ng/ml), which again presumably
overrides normal DSCR1 feedback attenuation (Figure 4D).
Both eNOS and BAD signaling converge on activation of
caspase-3, a key effector of the execution phase of apoptosis
(Porter and Janicke, 1999) (Figure S4B). We therefore assayed
caspase-3 activity spectrophotometrically in VEGF-treated
DSCR1 WT and DSCR1/ endothelial cells using a p-nitroani-
line chromophore-based assay (Gurtu et al., 1997). Caspase-3
activity was confirmed by blocking with the caspase-3-specific
inhibitor DEVD-fmk. Caspase-3 activity was significantly ele-
vated in DSCR1/ endothelial cells 36–48 hr after VEGF treat-
ment (100 and 500 ng/ml) as compared to wild-type endothelial
cells (Figure 4E). Furthermore, treatment of DSCR1/ endothe-
lial cell cultures with the broad pan-caspase inhibitor zVAD-fmk
rescued the VEGF-induced growth defect in DSCR1/ endo-
thelial cells (Figure 4F).
Tumor Growth in DSCR1/ Mice Is Restored upon
Suppression of Calcineurin Signaling
Finally, to ascertain whether hyperactivate calcineurin signaling
was causally responsible for suppressing tumor growth in
DSCR1/ mice, we asked whether systemic treatment of
DSCR1/ mice with the calcineurin inhibitor CsA could restore
tumor growth and angiogenesis. Mice were inoculated subcuta-
neously with RENCA tumor cells and then treated daily by oral
gavage with either low-dose (5 mg/kg) CsA (DSCR1/ mice)
or vehicle alone (WT and DSCR1/ mice). Low-dose CsA was
utilized to prevent any tumor-promoting effects observed with
high-dose CsA (Hojo et al., 1999). Rapid tumor growth was
restored in DSCR1/ mice treated with CsA (Figures 5A–
5C)—representative tumor weights and images are shown 28
days after tumor cell injection (Figures 5B and 5C). Furthermore,
immunofluorescence analysis with anti-CD31 antibody and
TUNEL reactivity confirmed that CsA treatment significantly sup-
pressed apoptosis in endothelial cells of vessels from tumors
grown in DSCR1/ mice (Figures 5D and 5E).
To confirm that these findings were reproducible in other
tumor models, we utilized a metastatic tumor model, by tail
vein injection of murine MC26 colon carcinoma cells into synge-
neic DSCR1 WT and DSCR1/ mice. Similar to our subcutane-
ous tumor model, the lungs of DSCR1 WT mice demonstrated
significant tumor burden as compared to DSCR1/ mice as as-
sessed by gross and histological analysis (Figures S5A–S5C).
Low-dose CsA (5 mg/kg) treatment of DSCR1/ mice restoredgrowth of lung metastases comparable to that of DSCR1 WT
mice (Figures S5A, S5C, and S5D). Finally, anti-CD31 and
TUNEL immunofluorescence demonstrated significantly fewer
TUNEL-positive endothelial cells in lungs from DSCR1/ mice
treated with CsA versus DSCR1/ mice treated with vehicle
alone (Figures S5D and S5E).
DSCR1/ Mice Demonstrate Decreased
VEGF-Dependent Angiogenesis
Taken together, our data indicate that endogenous DSCR1 acts
to attenuate VEGF signaling through calcineurin and NF-AT,
thereby fostering VEGF-induced mitogenesis. In the absence
Figure 5. Low-Dose Cyclosporin A Treatment Can Compensate for
Loss of DSCR1
(A) Subcutaneous tumor growth of the syngeneic mouse renal cell carcinoma
(RENCA) is restored in DSCR1/ mice when mice are treated with daily
low-dose cyclosporin A (CsA) (5 mg/kg) by oral gavage. Data are represented
as mean ± SEM.
(B) Average tumor weights 28 days after tumor cell inoculation of RENCA
tumors harvested from DSCR1/ mice treated with vehicle alone, DSCR1/
mice treated with daily low-dose CsA, and DSCR1 WT mice treated with
vehicle alone. Data are represented as mean ± SEM.
(C) Representative images of tumors harvested from the indicated group.
(D) Quantification of CD31- and TUNEL-positive cells in RENCA tumors
harvested from the indicated mice. Data are represented as mean ± SEM.
(E) RENCA tumors were immunostained for CD31 and TUNEL reactivity
demonstrating increased CD31-positive cells and decreased CD31+/TU-
NEL double-positive cells in DSCR1/ mice treated with daily low-dose
CsA as compared to DSCR1/ mice treated with vehicle alone. Scale
bar, 50 mM.Cancer Cell 13, 420–431, May 2008 ª2008 Elsevier Inc. 425
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Loss of DSCR1 Suppresses Tumor Angiogenesisof DSCR1, VEGF signaling elicits precocious and persistent
calcineurin activation, which triggers endothelial cell death,
potentially through BAD activation and induction of eNOS
(Figure 4C).
To explore the biological consequences ofDSCR1 inactivation
on angiogenesis in vivo, we assayed its effects on VEGF-induced
vessel growth in Matrigel implants and in the corneal eye assay
(Figures 6A and 6B). DSCR1/ mice exhibited a significant de-
crease in the numbers of vessels invading Matrigel pellets and in
response to VEGF pellets in the corneal eye assay, compared
with DSCR1 WT mice (Figures 6A and 6B). To examine the influ-
ence of DSCR1 status on vascular permeability in response
to VEGF, we used the Miles permeability assay. VEGF (50 ml;
1 ng/ml) was injected into the skin, and Evans blue levels in the
vessels and surrounding stroma were quantified spectrophoto-
metrically.DSCR1/mice showed significantly increased levels
of Evans blue dye in response to VEGF when compared with
DSCR1 WT mice (Figure 6C), consistent with defects in endothe-
lial cell proliferation or viability (Hashizume et al., 2000).
Figure 6. Decreased VEGF-Mediated Angiogenesis and Increased
Vascular Permeability in DSCR1/ Mice
(A) Increased vessel density in sections of Matrigel implants with VEGF after
7 days in DSCR1 WT as compared to DSCR1/ mice. Arrows indicate major
vessels. Scale bar, 50 mM.
(B) Comparison of corneal angiogenesis following VEGF injection in DSCR1
WT and DSCR1/ mice. Arrow indicates VEGF pellet. The histogram (right)
indicates quantification of vessel length and numbers. Data are represented
as mean ± SD.
(C) Miles permeability assay demonstrates increased VEGF-induced vascular
permeability in DSCR1/ mice as compared to WT mice. The histogram
(right) quantifies Trypan blue levels in the tissue. Data are represented as
mean ± SD.426 Cancer Cell 13, 420–431, May 2008 ª2008 Elsevier Inc.Loss of DSCR1 Causes Cerebral Hemorrhage
in Developing Embryos
Since angiogenesis is critical in embryonic development, we ex-
amined the effect ofDSCR1 loss during development. Mendelian
ratios of pups derived from numerous DSCR1+/ matings were
skewed, with fewer than the expected 25% of DSCR1/ off-
spring and suggestive of a variable penetrance, lethal, develop-
mental abnormality. Analysis at embryonic days 10 and 12 (E10
and E12) of >20 litters derived from DSCR1 heterozygous and
homozygous matings (n = 161 mice) revealed obvious cerebral
hemorrhage in15% of DSCR1/ embryos (Figure 7A), leading
to death and resorption before birth (data not shown). Hematox-
ylin and eosin images of vessels in the brain of DSCR1/ em-
bryos at E10 and E12 show abrupt appearance of leaky vessels
by E12, evident by extravasation of nucleated red blood cells into
the surrounding tissue (Figure 7B). Furthermore, E12 DSCR1/
embryos exhibit blood-filled ventricles that are absent in DSCR1
WT embryos at E12 (Figure 7C). Immunofluorescence analysis
using anti-DSCR1 mAb confirmed expression of DSCR1 in en-
dothelial cells lining vessels of WT E12 embryos that is absent
from DSCR1/ siblings (Figure 7D).
Previous studies have demonstrated that initiation of heart
valve morphogenesis at E9 requires calcineurin-NF-AT signaling
to repress VEGF expression in the myocardium and allow trans-
formation of endocardial cells into mesenchymal cells (Chang
et al., 2004). To determine how loss of DSCR1 might affect
VEGF levels in the embryo, we measured VEGF production in
E11 DSCR1 WT and DSCR1/ embryos by ELISA and found
VEGF to be significantly upregulated in DSCR1/ embryos
(Figure 7E). This increase in VEGF expression in DSCR1/
hearts was confirmed by anti-VEGF immunofluorescence on
sections of E11 heart from DSCR1+/+ and DSCR1/ mice
(Figure 7F).
DISCUSSION
The pivotal importance played by angiogenesis in providing
necessary oxygen and nutrients for the expansion and spread
of tumors is widely accepted (Folkman et al., 2006). Endothelial
cells comprise the principal component of blood vessels, and
tumor angiogenesis is driven by their proliferation and migration
in response to proangiogenic cytokines produced by both tumor
and stromal cells (Folkman et al., 2006). Interference with tumor
angiogenesis has now emerged as an important and mechanis-
tically distinct therapeutic strategy for treating cancer, thus
focusing great interest on how angiogenic signals are generated
by tumors, are sensed by endothelial cells, and exert their
effects. Our studies have identified a role for VEGF signaling
through the calcineurin-NF-AT pathway in the regulation of
tumor angiogenesis and growth. In particular, we have uncov-
ered the critical importance of DSCR1, the Down syndrome
candidate region-1 protein, as an endogenous attenuator of
the calcineurin-NF-AT pathway in the endothelium. Remarkably,
inactivation of DSCR1 leads to elevated and persistent activation
of calcineurin-NF-AT signaling, which triggers endothelial cell
death rather than mitogenesis and acts as a potent inhibitor of
tumor growth. Our data identify DSCR1 as a potential target
for antiangiogenic cancer therapy.
Cancer Cell
Loss of DSCR1 Suppresses Tumor AngiogenesisPrevious studies have shown that ectopic overexpression of
DSCR1 binds to, and potently suppresses, calcineurin activa-
tion—in turn, blocking nuclear relocalization and activity of the
NF-AT transcription factor (Iizuka et al., 2004; Hesser et al.,
2004; Minami et al., 2004; Yao and Duh, 2004). Since NF-AT
directly transactivates the inducible isoform of DSCR1,
DSCR1.Ex4 (Iizuka et al., 2004; Hesser et al., 2004; Minami
et al., 2004; Yao and Duh, 2004), the potential exists for a physi-
ological negative feedback loop by which induction of DSCR1
attenuates calcineurin-NF-AT signaling. To investigate this pos-
sibility in normal endothelial cells, we assayed calcineurin activa-
tion via subcellular localization of NF-ATc1 after VEGF treatment
of endothelial cells. VEGF exposure induced rapid (within 30 min)
localization of NF-AT to the endothelial cell nucleus, as
expected. However, despite sustained exposure of cells to
VEGF and, presumably, persistent elevation of intracellular
calcium, NF-AT relocalized back to the cytosol at later times
(Figure S6A). Such relocalization indicates attenuation of the
calcineurin signal and coincides temporally with the delayed
(1 hr), NF-AT-dependent induction of DSCR1.Ex4 expression
(Figures S6B and S6C). These data suggested a model whereby
DSCR1.Ex4 induction attenuates VEGF signaling by downregu-
lating calcineurin activity. To confirm this, we examined the level
and persistence of calcineurin-NF-AT signaling in endothelial
Figure 7. Loss of DSCR1 Leads to Cerebral
Hemorrhage in Developing Embryos
(A) Approximately 15% of DSCR1/ embryos
demonstrate cerebral hemorrhages (arrows) at
embryonic day 12 (E12) as compared to embry-
onic day 10 (E10).
(B) H&E images of vessels in the brain ofDSCR1/
embryos at E10 and E12 demonstrate leaky ves-
sels at E12 as indicated by nucleated red blood
cells in the surrounding tissue. Scale bar, 40 mM.
(C) H&E image of blood-filled ventricles in
DSCR1/ embryos as compared to wild-type
embryos at E12. Scale bar, 200 mM.
(D) Anti-DSCR1 mAb immunofluorescence analy-
sis of sections from DSCR1 WT and DSCR1/
mice demonstrate DSCR1 expression in endothe-
lial cells lining large vessels in wild-type mice.
Scale bar, 40 mM.
(E) VEGF levels are significantly increased in E11
DSCR1/ embryos as compared to DSCR1 WT
embryos measured by ELISA (*p < 0.05). Data
are represented as mean ± SD.
(F) Anti-VEGF immunofluorescence of the devel-
oping heart at E11 in DSCR1 WT and DSCR1/
mice. Images were captured using the same expo-
sure time, indicating increased VEGF expression
in DSCR1/ hearts. Scale bar, 200 mM.
cells deficient in DSCR1. As predicted,
DSCR1/ cells exhibited increased
rapidity of response and sensitivity to
VEGF-induced NF-AT nuclear localiza-
tion and induction of NF-AT target genes,
which was abrogated by cotreatment of
cells with the calcineurin inhibitor CsA.
Perhaps surprisingly, germline deletion of DSCR1 elicited
rather mild phenotypic effects—the majority of DSCR1/ mice
were normal, but 15% exhibited a lethal cerebral hemorrhage
phenotype. We speculate that VEGF levels during embryonic
development of DSCR1/ mice hover close to a threshold level
necessary to trigger constitutive calcineurin activation. Consis-
tent with this, VEGF levels inDSCR1/ embryos are significantly
higher than those of littermateDSCR1WT embryos. While loss of
DSCR1 in the developing heart might be expected to trigger
hyperactive calcineurin signaling and constitutive transrepres-
sion of VEGF via NF-AT (Chang et al., 2004), other studies
have shown that DSCR1 has dual roles in the heart and can either
potentiate or inhibit calcineurin signaling (Vega et al., 2002).
DSCR1-dependent physiological attenuation of VEGF-induced
calcineurin-NF-AT activation may well serve some role in forestal-
ling precocious endothelial cell activation during normal physio-
logical spikes of circulating or paracrine VEGF. Surprisingly, how-
ever, hyperactivation of the calcineurin-NF-AT pathway did not
lead to the obvious augmentation of growth responses of endo-
thelial cells to VEGF: rather,DSCR1/ endothelial cells exhibited
a substantial decrease in cell expansion when exposed to VEGF
due to the onset of endothelial apoptosis. This suggested that
hyperactivation of calcineurin-NF-AT in DSCR1/ cells reroutes
downstream calcineurin/NF-AT output to engage cell deathCancer Cell 13, 420–431, May 2008 ª2008 Elsevier Inc. 427
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pathways for this pathological cell death response—calcineurin-
dependent dephosphorylation and activation of the BH3 pro-
death protein BAD, and induction of the NF-AT target gene
eNOS. The extent to which either of these two proapoptotic effec-
tors contributes to the calcineurin hyperactivation apoptotic
phenotype in endothelial cells requires further studies.
Since hyperactivation of the calcineurin-NF-AT pathway in
DSCR1/ mice drives endothelial apoptosis, we suspected
that it might also limit the capacity of tumors to maintain a blood
supply. We confirmed this by demonstrating a substantial inhibi-
tion in initiation and progression of transplanted tumors in
DSCR1-deficient hosts. This suppression of tumor growth corre-
sponded with deficits in vascular expansion and elaboration, as
well as endothelial cell apoptosis, and was abrogated by sys-
temic treatment of mice with the calcineurin inhibitor CsA. Our
data do not exclude the possible roles of other mechanisms con-
tributing to tumor suppression in DSCR1/ mice. For example,
a direct role for NF-AT transcription factors has been proposed in
promoting invasion of breast cancers through inactivation of AKT
signaling (Jauliac et al., 2002). However, examination of AKT
activation in DSCR1 WT and DSCR1/ endothelial cells re-
vealed no significant differences in phospho-AKT expression
after VEGF treatment (data not shown), suggesting that DSCR
plays no direct role in regulating activation of AKT in endothelial
cells. The calcineurin-NF-AT-DSCR1 signaling pathway is also
known to play a critical role in immune cell activation (Ryeom
et al., 2003), which is thought to play an important role in
Figure 8. Model of VEGF-Calcineurin-
DSCR1 Regulation of Endothelial Cell Func-
tion
(A) Model depicting endothelial cell behavior upon
increasing VEGF-calcineurin signaling in the pres-
ence (left) and absence (right) of DSCR1.
(B) Model of tumor growth relative to DSCR1 levels
and calcineurin activity in endothelial cells. As
DSCR1 expression decreases, calcineurin activity
increases. Tumor growth occurs with moderate
levels of calcineurin activity in endothelial cells.
Too little calcineurin activity blocks endothelial
cell proliferation, and too much calcineurin activity
triggers endothelial cell apoptosis.
tumor growth. However, crossing our
DSCR1/ mice into the immunocom-
promised SCID background (Bosma
et al., 1988) had no effect on the inhibition
of tumorigenesis afforded by DSCR1 de-
ficiency (Figures S7A and S7B), exclud-
ing a significant role for T and B cells.
The idea that hyperactivation of VEGF
signaling pathways may actually suppress
endothelial cell growth is consistent with
observations that the response of normal
endothelial cells to VEGF is biphasic,
with very high levels of VEGF triggering
suppression of migration (Watanabe
et al., 2004) and initiation of apoptosis
(Figure 4B). More generally, the notion that an intermediate
strength of VEGF signaling is required for efficacious angiogenesis
is becoming an established and unifying theme. Conventional wis-
dom has dictated that more is generally better in chemotherapeu-
tic treatment targeting cancer cells. However, recent studies utiliz-
ing antiangiogenic agents directed specifically at endothelial cells
confirma biphasiceffectof these drugs (Folkman etal., 2006). If, as
we predict, tumor angiogenesis requires an optimal and intermedi-
ate level of angiogenic signaling, even slight perturbations of VEGF
signaling in the endothelium may prove to be an effective strategy
for disrupting tumor growth (Figure 8B). The delicate nature of the
equilibrium between DSCR1 and calcineurin-NF-AT suggests that
the calcineurin-NF-AT-DSCR1 pathway may be an unusually sen-
sitive target for antiangiogenic and anticancer therapies.
EXPERIMENTAL PROCEDURES
Generation of DSCR1 Null Mice
DSCR1/ mice were generated as previously described (Ryeom et al., 2003),
backcrossed ten generations, and maintained on C57Bl/6 and Balb/C back-
grounds. All procedures were performed according to protocols approved
by Children’s Hospital Institutional Animal Care and Use Committee.
Endothelial Cell Isolation
Three- to four-week-old DSCR1/ or WT mice were euthanized, and lungs
were removed, minced, and digested in 625 U/ml collagenase II (GIBCO) in
HBSS for 30 min at 37C. Cells were strained through a 100 mm strainer,
and collagenase activity was quenched with equal volume fetal calf serum.
Cells were resuspended in 5 ml sterile HBSS, loaded on an equal volume of
histopaque (Sigma) followed by centrifugation at 2000 rpm for 20 min. The428 Cancer Cell 13, 420–431, May 2008 ª2008 Elsevier Inc.
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ile HBSS + 0.5% BSA. Cells were then resuspended in 400ml HBSS + 0.5% BSA
and2ml CD31-FITC mAb (PharMingen) and rotated for 30minat 4C. Endothelial
cells were washed and resuspended in 90 ml of sterile MACS buffer (PBS + 0.5%
BSA/2 mM EDTA). Ten microliters of anti-FITC mAb conjugated to magnetic
beads (Miltenyi Corp.) was added to the cells and incubated for 15 min at 4C.
Next, 400ml MACS buffer was added to each cell preparation, and the entire vol-
ume was applied to Miltenyi charcoal columns attached to a magnet so that
CD31-bound cells adhered to the columns. Columns were washed three times
and removed from the magnet, and cells were released into sterile tubes. CD31-
boundcells were centrifuged at 1000 rpmfor5 minand resuspended inendothe-
lial cell media (DMEM, 15 mM HEPES, heparin, ECGS [Biomedical Technolo-
gies], 20% FBS, 5mM glutamine-pen-strep) and plated into a gelatin-coated
T-75 flask. Endothelial cells were reselected using FITC-lectin followed by incu-
bation with anti-FITC-conjugated magnetic beads. The same protocol for rese-
lection was followed as previously described for primary selection. Endothelial
cell purity was determined by anti-VEGFR2 immunofluorescence, and cells
were used for experiments between passages 2 and 6.
Proliferation
DSCR1/ and WT endothelial cells or human microvascular endothelial cells
(HMVEC; Cambrex) were plated at 12,500 cells per well in a 24-well tissue cul-
ture dish coated with 0.2% gelatin. Cells were incubated overnight in EBM
(Cambrex) with 0.5% FBS followed by incubation in EBM with 0.5% FBS (sup-
plemented with the indicated concentrations of recombinant VEGF [VEGF165,
NIH] or the indicated concentrations of CsA [Sigma]). Each condition was
plated in triplicate, and cells were counted at the indicated times on a Coulter
counter. Data are presented as the mean ± SEM. For 3H-thymidine uptake,
endothelial cells were plated 1 3 104 cells/ml with 0.2% FBS for 14–18 hr
followed by addition of the indicated concentration of recombinant VEGF or
CsA for 24–48 hr. Cells were pulsed for 16–24 hr with 1 mCi/ml 3H-thymidine,
fixed in 10% (w/v) trichloroacetic acid, and solubilized in scintillation fluid
and counted in a scintillation counter. Z-VAD-fmk (Alexis Biochemicals) was
solubilized in DMSO and added at a final concentration of 20 mM.
Western Blot
Equal numbers of DSCR1/ and WT endothelial cells were plated in 48-well
dishes and treated with 10 mg/ml VEGF for the indicated times and lysed in
sample buffer. Lysates were separated by SDS-PAGE, transferred to nitrocel-
lulose membranes, and probed for DSCR1 expression (14B4 monoclonal
antibody at 1:200) (Ryeom et al., 2003) and b-actin (1:10,000; Abcam). Blots
were incubated with goat anti-mouse HRP-conjugated secondary (1:1000;
Zymed) for 1 hr followed by ECL (Amersham) for signal detection.
For phospho-BAD and total BAD expression, 7500 DSCR1/ and DSCR1
WT endothelial cells were plated in 24-well tissue culture dishes and incubated
in 0.1% FBS overnight followed by incubation with the indicated concentra-
tions of recombinant VEGF165 for 48 hr. Cells were lysed in 1% NP-40 with pro-
tease inhibitors, precleared with 50% slurry of washed sepharose beads in
PBS, then incubated overnight at 4C with 1 mg anti-BAD mAb (New England
Biolabs) followed by a 2 hr incubation with 50% slurry of protein G-sepharose
beads (Amersham). Beads were washed three times with 1% NP40 lysis
buffer, resuspended in sample buffer, separated by SDS-PAGE, and probed
with anti-Phospho-BAD antibody (New England Biolabs).
ATP Viability and Caspase-3 Assay
DSCR1/ and WT endothelial cells (13 106) were plated in 96-well plates and
stimulated with EBM plus 1% FBS and the indicated concentrations of VEGF.
Cell viability was measured after 3 days with a luminescence ATP assay (Cell
Titer-Glo, Promega) measuring release of ATP from live cells. Caspase-3 activ-
ity was measured after 36–48 hr following addition of cell lysis buffer as per the
manufacturer’s instructions (BD ApoAlert Caspase Colorimetric Assay Kit,
Clontech). Caspase-3 activity was measured with the substrate DEVD-pNA
and inhibited with DEVD-fmk. Absorbance was measured at 405 nm. Data
are presented as the mean ± SEM.
Immunohistochemistry
Mice were euthanized and tumors were harvested and fixed in neutral-buff-
ered formalin for paraffin sections. Formalin-fixed, paraffin-embedded tumorsections were deparaffinized by successive incubations in xylene, 95% etha-
nol, 90% ethanol, 70% ethanol followed by PBS. Epitopes were unmasked
with 20 mg/ml proteinase K in PBS at room temperature (RT) for 30 min and
rinsed twice in PBS with 0.3% Triton X-100 (PBS-T). Sections were immuno-
stained with rat anti-CD31 mAb (1:50; PharMingen) or goat anti-mouse-
aSMA mAb (1:500; Neomarkers) overnight at RT followed by incubation for
2 hr with goat anti-rat Alexa 594-conjugated secondary antibody (1:500;
Molecular Probes) or goat anti-mouse Alexa 488 (1:500; Molecular Probes),
respectively, for 2 hr at RT.
Sections were TUNEL stained using the Dead-End labeling kit (Promega)
following the manufacturer’s instructions. In brief, sections were incubated for
15 min in equilibration buffer followed by incubation with fluoresceinated rdNTPs
and terminal deoxy transferase for 60 min at 37C. Reactions were stopped by
incubation in 2xSSC for 15 min followed by serial washes in PBS-T. Cell nuclei
werestainedwithHoechstdye (1mg/ml;Sigma). ImageswereobtainedonaZeiss
microscope and analyzed using AxioVision 4.0 software (Carl Zeiss Vision).
Immunofluorescence
Endothelial cells (10 3 105/ml) were plated onto gelatin-coated glass cover-
slips overnight. Cells were fixed with paraformaldehyde for 7 min at RT fol-
lowed by blocking in 3% milk in Tris-buffered saline with Tween (TBS-T) for
45 min. Anti-VEGF-R2 mAb (1:500; Cell Signaling) or DSCR1 mAb (1:500)
(Ryeom et al., 2003) or anti-Annexin V mAb (1:100; Santa Cruz) or isotype-
matched control antibodies were added for 1 hr at RT. Endothelial cells stained
with Annexin mAb were not permeabilized to detect cell surface expression of
annexin V. Cells were washed with PBS-T before the addition of rabbit
anti-mouse-Alexa 594 (1:500; Molecular Probes) for 30 min at RT protected
from light. Nuclei were stained with 1% Hoechst dye for 1 min. Cells were
extensively washed with PBS-T, mounted, and viewed on a fluorescence mi-
croscope. For uptake of 4,5-diaminofluorescein diacetate (DAF-2DA; Alexis
Biochemicals), a fluorescent indicator of NO, endothelial cells were treated
with the indicated conditions, washed free of serum, and incubated with
DAF-2DA diluted in PBS (1:500) for 30–60 min, washed extensively, and
viewed on a fluorescence microscope.
Matrigel Plug Assay
Matrigel plug assays were performed as described (Montrucchio et al., 2000).
Briefly, Matrigel with VEGF (BD Bioscience) in liquid form at 4C was injected
(0.5 ml per mouse) intraperitoneally into wild-type and DSCR1 null mice along
the midline. Mice were euthanized after 7 and 14 days, and gels were recov-
ered and processed for histology.
Corneal Micropocket Assay
Corneal angiogenesis assays were performed as described (Kenyon et al.,
1997). Eight- to ten-week-old DSCR1 null and wild-type mice were anesthe-
tized, and topical anesthetic was applied to both eyes before incision with
a 30 angle microknife. A pocket is made perpendicular to the incision with
a von Graefe cataract knife. A 0.4 mm3 0.4 mm3 0.2 mm sucrose aluminum
sulfate pellet coated with hydron polymer type NCC containing 160 ng VEGF
was inserted into the pocket and implanted 0.7–1.0 mm from the limbus.
Five days postsurgery, animals’ eyes are examined with a slit lamp microscope
and any vessel growth is measured.
Skin Miles Vascular Permeability Assay
Six- to eight-week-old mice were anesthetized and injected intravenously with
100 ml of a 1% Evans blue dye in normal saline solution. After 10 min, 1 ng/ml of
recombinant VEGF165 (NIH) in 50 ml normal saline was injected intradermally
into the shaved back of the mice. After 20 min mice were sacrificed, skin was
removed, and equivalent-sized skin biopsies were placed in 500 ml formamide
for 5 days at RT for complete extraction of blue dye. Concentration of dye was
quantified by absorbance readings of 620 nm.
Tumor Miles Permeability Assay
Tumor-bearing mice were anesthetized and injected intravenously with 100 ml
of a 1% Evans blue dye in normal saline solution. After 30 min, an 18 gauge
cannula was inserted into the left ventricle, and an exit incision was made in
the right atrium. Mice were perfused systemically with PBS for 30 min at a pres-
sure of 120 mm Hg. Tumors was then removed and placed into 2 ml formamideCancer Cell 13, 420–431, May 2008 ª2008 Elsevier Inc. 429
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at 620 nm with optical densitometry values normalized to tumor volume.
Tumor Models
Murine MC26, murine RENCA, or B16F10 melanoma cells (1 3 106) were
injected subcutaneously into the flanks of 6- to 8-week-old DSCR1 null or
wild-type mice. Tumors were measured with calipers, and volume was calcu-
lated by the formula TV = (length 3 width2) 3 0.52 (O’Reilly et al., 1997). For
metastatic tumor models, 1 3 106 MC26 tumor cells were injected intrave-
nously into 6- to 8-week-old DSCR1/ or littermate WT mice. Mice were
euthanized at the indicated days after tumor cell injection, and lungs were iso-
lated, weighed, and fixed in neutral-buffered formalin for histology. Data are
presented as the mean ± SEM.
CsA Treatment
Murine MC26 cells (13 106) were injected intravenously into 6- to 8-week-old
DSCR1/ or littermate WT mice. CsA (5 mg/kg in olive oil) was administered
every other day by oral gavage starting on the day of tumor cell injection. On
the indicated days after tumor inoculation, mice were euthanized, and pulmo-
nary metastases and tumor burden were assessed grossly and histologically.
SUPPLEMENTAL DATA
The Supplemental Data include seven supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/5/420/
DC1/.
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